Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update
by Mitch Edgeman · The Markets DailyCreative Medical Technology Holdings, Inc. (NASDAQ:CELZ – Get Free Report) was the recipient of a large decrease in short interest during the month of August. As of August 31st, there was short interest totaling 272,812 shares, a decrease of 53.3% from the August 15th total of 584,609 shares. Based on an average trading volume of 1,219,586 shares, the days-to-cover ratio is presently 0.2 days. Approximately 4.2% of the company’s shares are sold short.
Analysts Set New Price Targets
Several analysts recently weighed in on CELZ shares. Weiss Ratings upgraded shares of Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Roth Capital restated a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Finally, Wall Street Zen raised Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold”.
Check Out Our Latest Research Report on Creative Medical Technology
Creative Medical Technology Stock Down 4.2%
CELZ stock traded down $0.04 during midday trading on Wednesday, hitting $0.85. The company’s stock had a trading volume of 120,030 shares, compared to its average volume of 3,490,445. The firm has a 50-day simple moving average of $1.00 and a 200-day simple moving average of $1.67. The firm has a market capitalization of $5.59 million, a P/E ratio of -0.41 and a beta of 2.04. Creative Medical Technology has a 52-week low of $0.62 and a 52-week high of $6.25.
Creative Medical Technology (NASDAQ:CELZ – Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, sell-side analysts expect that Creative Medical Technology will post -1.18 earnings per share for the current fiscal year.
About Creative Medical Technology
Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.
The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.